Ethical Profile

Mixed.

Alterity Therapeutics Limited focuses on developing treatments for debilitating neurodegenerative diseases like Parkinson's, Alzheimer's, and Multiple System Atrophy (MSA). Their lead candidate, ATH434, is in Phase II clinical trials for MSA, addressing a significant unmet medical need. While their core mission aligns with improving health, as a pharmaceutical company, Alterity Therapeutics may be required to conduct animal testing for drug approval, which critics point to as a potential ethical conflict. Reports suggest insufficient public data on their practices in areas like fair pay, ethical sourcing, or environmental impact.